R&D News | pharmaphorum

News

UK puts £50m behind expanded clinical trials drive

The UK has awarded nearly £50m in funding for equipment to help the NHS carry out commercial clinical trials, with a focus on primary care capacity.

News

Quell takes new Treg into clinic after transplant study halt

Quell Therapeutics changes tack, starting trials of a CAR-Treg in rheumatoid arthritis and systemic sclerosis and parking its transplant therapy.

News

United's PAH drug clears phase 3 trial, setting up filings

United Therapeutics will file ralinepag as a treatment for pulmonary arterial hypertension later this year, but can it compete in a crowded market?

News

New FDA knockback hits uniQure and Huntington patients hard

uniQure looks like it may have to run another trial of its Huntington's disease gene therapy AMT-130, delaying the highly anticipated programme.

News

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?

News

New biotech Atrium born out of Novartis/Avidity marriage

Atrium Therapeutics has launched with $270m in funding and two preclinical siRNA candidates for rare genetic cardiomyopathies.

UK puts £50m behind expanded clinical trials drive

Quell takes new Treg into clinic after transplant study halt

United's PAH drug clears phase 3 trial, setting up filings

New FDA knockback hits uniQure and Huntington patients hard

After phase 3 clean sweep, Roche plans oral BTK filing in MS

New biotech Atrium born out of Novartis/Avidity marriage

Ultragenyx to slash costs after Angelman trial failure

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks